Novartis: FDA approves Beovu update
(CercleFinance.com) - Novartis has announced that the US Food and Drug Administration (FDA) has approved an update of prescription information for Beovu (brolucizumab) to guide healthcare professionals in treating patients with wet AMD.
The update includes the characterisation of adverse events, retinal vasculitis and retinal vascular occlusion within the scope of intraocular inflammation observed in the HAWK & HARRIER trials.
Novartis has assembled a fully dedicated team collaborating with the world's leading external experts, leveraging the collective multidisciplinary expertise to examine the root causes, potential risk factors and mitigation of these adverse events, it said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The update includes the characterisation of adverse events, retinal vasculitis and retinal vascular occlusion within the scope of intraocular inflammation observed in the HAWK & HARRIER trials.
Novartis has assembled a fully dedicated team collaborating with the world's leading external experts, leveraging the collective multidisciplinary expertise to examine the root causes, potential risk factors and mitigation of these adverse events, it said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.